CHATSWORTH, Calif., July 20, 2009 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS) announced today that, ahead of its planned financial analysts breakfast briefing on Wednesday, July 22 at the AACC Annual Meeting and Clinical Lab Expo in Chicago, the Company will host a conference call on Tuesday, July 21, 2009, at 4:30 p.m. Eastern time to provide preliminary second quarter operating results and update to shareholders and investors. The discussion will be led by Cesar Garcia, Chairman, President and Chief Executive Officer, along with other members of his senior executive staff.
Date: July 21, 2009 Time: 4:30 PM ET
To listen via live webcast, go to the IRIS website at: http://proiris.com or http://investor.shareholder.com/media/eventdetail.cfm?eventid=71003&CompanyID=ABEA-2RC4AZ&e=1&mediaKey=0F059E45A57CA28895D6144DD88C64FA
To schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=36413&k=0E213741
To participate in the teleconference, please dial (10 min. before conference is scheduled to begin):
Domestic toll-free: 1-888-298-3511 International: +719-325-2100
If you are unable to participate during the live conference call and webcast, the conference call audio cast will be archived and available for replay in the Investor Relations section of the Company's website at http://www.proiris.com for approximately 90 days.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,230 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA(r), platform, with applications in oncology and infectious disease. For more information visit www.proiris.com.